Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more
Athira Pharma Inc - Asset Resilience Ratio
Athira Pharma Inc (ATHA) has an Asset Resilience Ratio of 14.49% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Athira Pharma Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Athira Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.35 Million | 14.49% |
| Total Liquid Assets | $4.35 Million | 14.49% |
Asset Resilience Insights
- Moderate Liquidity: Athira Pharma Inc has 14.49% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Athira Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Athira Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Athira Pharma Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Athira Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.83% | $2.84 Million | $58.78 Million | -30.64pp |
| 2023-12-31 | 35.47% | $56.84 Million | $160.25 Million | -4.97pp |
| 2022-12-31 | 40.43% | $104.38 Million | $258.15 Million | -2.71pp |
| 2021-12-31 | 43.14% | $143.22 Million | $332.01 Million | -1.24pp |
| 2020-12-31 | 44.38% | $124.06 Million | $279.56 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $2.19 Million | -- |
| 2018-12-31 | 30.41% | $1.50 Million | $4.93 Million | -- |